Topic: Clinical Trial Results
Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.
Novartis is gunning for an OK for Cosentyx in non-radiographic axial spondyloarthritis, and it’s now got one-year data to make its case to the FDA.
Roche’s Tecentriq was the first in its class to break into the bladder cancer arena. And it now could be the first to expand its reach there, too.
Novartis envisioned $5 billion in peak sales for its cardiovascular drug Entresto, but, after a major trial flop, that goal appears out of reach.
Incyte's bone marrow drug Jakafi has been pitching in blockbuster-level sales, and now it has a new approval that could give it another boost.
Join this webinar to learn the five characteristics of a unified platform and how each benefits clinical research both for a single trial and across your suite of research efforts.
Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.
Pfizer's abrocitinib, a JAK1-specific inhibitor, has met all co-primary and key secondary endpoints in a late-stage eczema study.
New analysis found Mayzent had meaningful benefits on cognitive processing speed in patients with secondary progressive multiple sclerosis.
Eli Lilly had high hopes in oncology with its oncology drug, Lartruvo. Now, with the failed drug in full retreat, Lilly hopes to keep current patients.